Abstract
Introduction: meningeal cryptococcosis is a universal opportunistic infection that presents variable prognostic factors, especially in immunosuppressed patients.
Objective: to identify clinical and paraclinical variables associated with the outcome at the end of hospitalization in patients with meningeal cryptococcosis treated at a tertiary care hospital in Bogotá, Colombia.
Materials and methods: descriptive observational study. The information was obtained through records of medical records of patients with a confirmed diagnosis of meningeal cryptococcosis during the period 2016-2021.
Results: 54 cases were analyzed. 85,2?% men, with a median age of 38 years. The main symptom was headache (74,1?%), with an average duration of 30 days prior to admission. 83,3?% had a diagnosis of HIV, with CD4 levels below 50 cell/mm3 and high viral load counts. The cerebrospinal fluid showed in more than 50?% intracranial hypertension, pleocytosis of lymphocyte predominance, hyperprotein- orrhachia and hypoglycorrhachia. The most frequent type of pathogen isolated was C. neoformans var neoformans. And the most prevalent variables in the group of patients who died were the presence of pleocytosis in CSF (p?=?0,025), culture for positive fungus (p?=?0,02) and isolation of C. neoformans var neoformans (p?=?0,03).
Discussion: meningeal cryptococcosis is a frequent pathology in men, in the fourth decade of life and with HIV infection, however, the factors related to mortality seem to vary depending on the geographical location.
Conclusion: in our study, the most prevalent factors were the presence of pleocytosis in CSF, positive culture, isolation of C. neoformans var neoformans.
References
Fisher KM, Montrief T, Ramzy M, Koyfman A, Long B. Cryptococcal meningitis: a review for emergency clinicians. Intern Emerg Med. 2021;16(4):1031-42. https://doi.org/10.1007/s11739-020-02619-2
Bennett JE, Blaser MJ, Dolin R. Mandell, Douglas, and Bennett's principles and practice of infectious diseases [Internet]. Elsevier; 2015 [consultado el 12 de febrero del 2022]. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/C20121000756
Bennett Maziarz EK, Perfect JR. Cryptococcosis. Infect Dis Clin N Am. 2016;30(1):179-206. https://doi.org/10.1016/j.idc.2015.10.006
Firacative C, Lizarazo J, Illnait-Zaragozí MT, Castañeda E, Arechavala A, Córdoba S, et al. The status of cryptococcosis in Latin America. Mem Inst Oswaldo Cruz. 2018;113(7):1-23. https://doi.org/10.1590/0074-02760170554
Firacative C, Meyer W, Castañeda E. Cryptococcus neoformans and Cryptococcus gattii species complexes in Latin America: a map of molecular types, genotypic diversity, and antifungal susceptibility as reported by the Latin American Cryptococcal Study Group. J Fungi (Basel). 2021;7(4):282. https://doi.org/10.3390/jof7040282
Lizarazo J, Escandón P, Agudelo CI, Firacative C, Meyer W, Castañeda E. Retrospective study of the epidemiology and clinical manifestations of Cryptococcus gattii infections in Colombia from 1997-2011. PLoS Negl Trop Dis. 2014;8(11): e3272. https://doi.org/10.1371/journal.pntd.0003272
Noguera MC, Escandón P, Castañeda E. Cryptococcosis in Atlántico, Colombia: an approximation of the prevalence of this mycosis and the distribution of the etiological agent in the environment. Rev Soc Bras Med Trop. 2015;48(5):580-6. https://doi.org/10.1590/0037-8682-0178-2015
Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009;23(4):525-30. https://doi.org/10.1097/QAD.0b013e328322ffac
Lizarazo J, Linares M, de Bedout C, Restrepo A, Agudelo C. Estudio clínico y epidemiológico de la criptococosis en Colombia: resultados de nueve años de la encuesta nacional, 1997-2005. Biomédica. 2007 [consultado el 18 de julio del 2022]. 27:94-109. https://doi.org/10.7705/biomedica.v27i1.236
Dromer F, Mathoulin-Pélissier S, Launay O, Lortholary O, Achard J, Chabasse D, et al. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D Study. PLoS Med. 2007;4(2):e21. https://doi.org/10.1371/journal.pmed.0040021
Li M, Chen Z, Xu L, Gan Z, Peng F, Liu J. A comparison of the clinical characteristics and outcomes of cryptococcal meningitis in HIV-negative Individuals with and without immunosuppression. Neurologist. 2019;24(1):1-5. https://doi.org/10.1097/NRL.0000000000000221
Sow D, Tine RC, Sylla K, Djiba M, Ndour CT, Dieng T, et al. Cryptococcal meningitis in Senegal: epidemiology, laboratory findings, therapeutic and outcome of cases diagnosed from 2004 to 2011. Mycopathologia. 2013;176(5-6):443-9. https://doi.org/10.1007/s11046-013-9710-8
Instituto Nacional de Salud. VIH, SIDA y muerte por SIDA, Colombia 2020. Disponible en: https://www.ins.gov.co/buscador-eventos/Informesdeevento/VIH-SIDA_2020.pdf
Vergara I, Saavedra M, Saravia J, González G, Lorenzana P, Acosta C, et al. Criptococosis del sistema nervioso central. Estudio de 32 casos 1975-1991. Acta Med Colomb. 1993;199-210.
Jarvis JN, Bicanic T, Loyse A, Namarika D, Jackson A, Nussbaum JC, et al. Determinants of mortality in a combined cohort of 501 patients with HIV-associated cryptococcal meningitis: implications for improving outcomes. Clin Infect Dis. 2014;58(5):736-45. https://doi.org/10.1093/cid/cit794
Lizarazo J, Chaves O, Peña Y, Escandón P, Agudelo CI. Comparación de los hallazgos clínicos y de supervivencia entre pacientes VIH positivos y VIH negativos con criptococosis meníngea en un hospital de tercer nivel. Acta Med Colomb. 2012;37(2):49-61.
Lee YC, Wang JT, Sun HY, Chen YC. Comparisons of clinical features and mortality of cryptococcal meningitis between patients with and without human immunodeficiency virus infection. J Microbiol Immunol Infect. 2011;44(5):338-45. https://doi.org/10.1016/j.jmii.2010.08.011
Lessells RJ, Mutevedzi PC, Heller T, Newell ML. Poor long-term outcomes for cryptococcal meningitis in rural South Africa. S Afr Med J. 2011;101(4):251-2. https://doi.org/10.7196/SAMJ.4378
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.